1. Market Research
  2. > Healthcare
  3. > Diagnostics Market Trends
  4. > Global Liquid Biopsy Market Outlook to 2020

Global Liquid Biopsy Market Outlook to 2020

  • February 2016
  • -
  • RNCOS
  • -
  • 90 pages

The recent discovery of liquid biopsy technology and its wide applicability have sparked off a lot of interest among researchers along with the commercial players. Owing to the same, there are numerous clinical trials being organized all over the world in order to assess the potential of liquid biopsy in various fields such as cancer, prenatal screening and organ transplant monitoring.

As indicated by the new estimation carried out in our most recent study, the global liquid biopsy industry is expected to cross US$ 1 Billion mark by the end of 2020, as new products, especially those in the advanced stage of clinical studies or with pending approvals, might enter the market to support the development.

According to RNCOS’ new research report “Global Liquid Biopsy Market Outlook to 2020”, a major focus has been on the development of innovative products based on different technologies and different sample types. In this context, the study provides present and future outlooks for the two broad categories of liquid biopsy market; by technology and by sample type. The former comprises of the three marker categories that dominate liquid biopsy today: Circulating Tumor Cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (or exosomes). On the other hand, the latter includes the two major bodily fluid samples: blood and urine. According to report, blood is the most widely used sample type, and is expected to remain the largest market based on sample type in the coming years as well. The report also includes a detailed pipeline analysis of upcoming liquid biopsy products along with the sample type utilized.

Most of the current research is focused on utilizing liquid biopsy for diagnostic purposes, such as response evaluation, expression profiling, tumor diagnosis and treatment monitoring in a blood test. The flexible design of the liquid biopsy platform supports a variety of research areas, including Stem cell research, Oncology, Infectious Disease, Immunology, Endothelial Cells, and Fetal Cells.

The market has been divided into four major geographic regions - North America, Europe, Asia and Rest of the World. North America is the largest market for the liquid biopsy. This high share is attributed to relative high adoption of liquid biopsy, coupled with launch of new and advanced products in the market. The Asian market is poised to witness the highest growth owing to increasing focus of players in this region.

RNCOS, in its report, further covers how major trends and drivers, mainly therapy monitoring, increasing use of Circulating tumor DNA for cancer screening, growing interest of venture capital firms, etc. will propel the industry’s growth. An analysis has also been done of a few factors limiting the growth of the industry.

After an exhaustive study of the industry, RNCOS has laid out the primary market players which are engaged in providing liquid biopsy based tools and services. These players are working over a vast variety of products, such as blood based tests, urine based tests, assays and instruments for sample extraction, amplification and purification, and constantly upgrading their portfolio to keep up with the latest developments in the field. Some of these players include NeoGenomics, Trovagene, Guardant Health, Biocept, Biocartis, and Pathway Genomics.

Overall, even though the market is in its nascent stage at the moment, it is expanding at an almost exponential rate. With new players entering the market, increase in the number of collaborations and strong support from research institutes, the liquid biopsy market is bound to witness rampant diversification and growth in the coming years.

Table Of Contents

Global Liquid Biopsy Market Outlook to 2020
1. Analyst View
2. Research Methodology
3. Liquid Biopsy - An Introduction
4. Market Dynamics
4.1 Market Drivers
4.1.1 High Prevalence of Cancer
4.1.2 Technological Advancements in Personalized Therapies
4.1.3 Increasing Demand for Minimally-Invasive Biopsy Techniques
4.1.4 Lower Cost
4.1.5 Growing Interest of Venture Capital Firms
4.2 Market Restraints
4.2.1 A Less-Defined Regulatory Environment
4.2.2 Comparatively Low Concentration of Molecular Biomarkers in Body Fluids
4.2.3 Need for Proper Handling and Storage of the Samples
4.3 Market Opportunities
4.3.1 Exosomes Offer Great Advantages as Source Materials
4.3.2 Next Generation Sequencing Offers Significant Opportunity
4.3.3 Prenatal Screening and Organ Transplantation: Upcoming Applications
4.3.4 Growing Researches on Cerebrospinal Fluid as Sample Source
4.4 Industry Trends
4.4.1 Strong Preference for ctDNA Among Various Biomarkers
4.4.2 Blood: The Most Widely Used Sample
5. Global Liquid Biopsy Market Outlook to 2020
6. Global Liquid Biopsy Market Size by Technology
6.1 Circulating Tumor Cells (CTCs)
6.2 Circulating Tumor DNA/Cell free DNA (ctDNA/cfDNA)
6.3 Exosomes
7. Global Liquid Biopsy Market Size by Sample Type
7.1 Blood
7.2 Urine
8. Global Liquid Biopsy Market Size by Geography
8.1 North America
8.2 Europe
8.3 Asia
8.4 Rest of the World (RoW)
9. Pipeline Analysis
10. Key Player Analysis
10.1 Personal Genome Diagnostics
10.2 Guardant Health, Inc.
10.3 Pathway Genomics
10.4 NeoGenomics, Inc.
10.5 RainDance Technology
10.6 Trovagene, Inc.
10.7 Circulogene Theranostics
10.8 Biocartis
10.9 Cynvenio Biosystems, Inc.
10.10 Biocept, Inc.
10.11 ANGLE plc
10.12 MDxHealth
10.13 Clearbridge BioMedics Pte Ltd
10.14 Exosome Diagnostics, Inc.

List of Figures:

Figure 5-1: Global - Liquid Biopsy Market (Million US$), 2015 and 2020
Figure 6-1: Global - Liquid Biopsy Market by Technology (%), 2015
Figure 6-2: Global - Liquid Biopsy Market for CTCs (Million US$), 2015 and 2020
Figure 6-3: Global - Liquid Biopsy Market for ctDNA (Million US$), 2015 and 2020
Figure 6-4: Global - Liquid Biopsy Market for Exosomes (Million US$), 2015 and 2020
Figure 7-1: Global - Liquid Biopsy Market by Sample Type (%), 2015
Figure 7-2: Global - Blood Based Liquid Biopsy Market (Million US$), 2015 and 2020
Figure 7-3: Global - Urine Based Liquid Biopsy Market (Million US$), 2015 and2020
Figure 8-1: Global - Liquid Biopsy Market by Geography (%), 2015
Figure 8-2: North America - Liquid Biopsy Market (Million US$), 2015 and 2020
Figure 8-3: Europe - Liquid Biopsy Market (Million US$), 2015 and 2020
Figure 8-4: Asia - Liquid Biopsy Market (Million US$), 2015 and 2020

List of Tables:

Table 4-1: Global - Cancer Incidence by Region (Million), 2020
Table 4-2: Comparison of the Analysis Capability of CTC's, cfDNA and Exosomes
Table 8-1: North America - Cancer Incidences by Type ('000), 2015 and 2020
Table 8-2: Europe - Cancer Incidences by Type ('000), 2015 and 2020
Table 8-3: Asia - Cancer Incidences by Type ('000), 2015 and 2020
Table 9-1: Pipeline Analysis for Liquid Biopsy
Table 10-1: Personal Genome Diagnostics - Liquid Biopsy Associated Product Line
Table 10-2: Guardant Health - Liquid Biopsy Associated Product Line
Table 10-3: Pathway Genomics - Liquid Biopsy Associated Product Line
Table 10-4: NeoGenomics, Inc. - Key Financials (Million US$), 2012-2014
Table 10-5: NeoGenomics - Liquid Biopsy Associated Product Line
Table 10-6: RainDance Technologies - Key Financials (Million US$), 2012-2014
Table 10-7: RainDance Technology - Liquid Biopsy Associated Product Line
Table 10-8: Trovagene - Key Financials (Million US$), 2013-2015
Table 10-9: Trovagene - Liquid Biopsy Associated Product Line
Table 10-10: Circulogene Theranostics - Liquid Biopsy Associated Product Line
Table 10-11: Biocartis Group NV - Key Financials (Million US$), 2012-2014
Table 10-12: Biocartis - Liquid Biopsy Associated Product Line
Table 10-13: Cynvenio Biosystems, Inc. - Liquid Biopsy Associated Product Line
Table 10-14: Biocept, Inc. - Key Financials (Million US$), 2012-2014
Table 10-15: Biocept, Inc. - Liquid Biopsy Associated Product Line
Table 10-16: ANGLE plc - Key Financials (Million US$), 2013-2015
Table 10-17: ANGLE plc - Liquid Biopsy Associated Product Line
Table 10-18: MDxHealth - Key Financials (Million US$), 2012-2014
Table 10-19: MDxHealth - Liquid Biopsy Associated Product Line
Table 10-20: Clearbridge BioMedics Pte Ltd - Liquid Biopsy Associated Product Line
Table 10-21: Exosome Diagnostics, Inc. - Liquid Biopsy Associated Product Line

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Liquid Biopsy Market: Global Industry Analysis and Opportunity Assessment 2016-2026

Liquid Biopsy Market: Global Industry Analysis and Opportunity Assessment 2016-2026

  • $ 5000
  • Industry report
  • August 2016
  • by Future Market Insight Global & Consulting Pvt Ltd

Report Synopsis This report by Future Market Insights (FMI) examines the ‘Liquid Biopsy Market’ for the period 2016–2026. The primary objective of the report is to offer updates and information ...

Breast Biopsy Device Market Analysis By Test Type, By Product, By Guidance Type, By Region And Segment Forecasts To 2024

Breast Biopsy Device Market Analysis By Test Type, By Product, By Guidance Type, By Region And Segment Forecasts To 2024

  • $ 4950
  • Industry report
  • August 2016
  • by Grand View Research

The breast biopsy device market is expected to reach USD 911.2 million by 2024, according to a new report by Grand View Research, Inc. The Breast biopsy device market is projected to grow at a productive ...

Liquid Biopsy Market Size & Forecast By Application, By Sample Type, By Biomarker Type, By Technology and Trend Analysis from 2013 to 2030

Liquid Biopsy Market Size & Forecast By Application, By Sample Type, By Biomarker Type, By Technology and Trend Analysis from 2013 to 2030

  • $ 4950
  • Industry report
  • September 2016
  • by Grand View Research

Global liquid biopsies market is anticipated to reach 5,958.3 million by 2030, according to a new report by Grand View Research, Inc. As these less invasive biopsies are able to address a number of significant ...


Download Unlimited Documents from Trusted Public Sources

Biopsy Industry in the US

  • October 2016
    7 pages
  • Biopsy  

    Magnetic Resona...  

    Cancer  

  • United States  

View report >

Biopsy Industry in the US

  • August 2016
    2 pages
  • Biopsy  

  • United States  

    North America  

View report >

Biopsy Industry in the US

  • August 2016
    4 pages
  • Biopsy  

  • United States  

View report >

Related Market Segments :

Biopsy

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.